Diabetes drug withdrawn after reports of hepatic events

J. Wise
DOI: https://doi.org/10.1136/BMJ.315.7122.1559N
1997-12-13
British Medical Journal
Abstract:The new diabetes drug troglitazone (Romozin) has been withdrawn from the market in Britain after an increasing number of reports of severe hepatic adverse events. The Food and Drug Administration in the United States, however, has decided that the benefits of treatment outweigh the risks, provided that patients receiving troglitazone are monitored frequently for …
What problem does this paper attempt to address?